ABT 44.23 Abbott Laboratories $ABT Hit a 52 week h
Post# of 70
Posted On: 11/14/2014 10:08:11 AM
ABT 44.23 Abbott Laboratories $ABT Hit a 52 week high of 44.59 Closing the day 09:45 at 44.23 -0.36 -0.81% With a day low of 44.22 and a total volume of 210,716.
ABT Recent Posts: http://investorshangout.com/Abbott-Laboratories-ABT-49973/
ABT Abbott Laboratories Recent Headline News
Global Clinical Chemistry Analyzer (Basic Metabolic, Electrolyte, Liver, Lipid, Renal, Thyroid Function, Specialty Chemicals) Market - Forecast to 2019
M2 - Fri Nov 14, 5:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/jzzrg4/clinical) has announced the addition of the "Clinical Chemistry Analyzer Market by Product, Test Type, End User - Global Forecast to 2019" report to their offering. Clinical chemistry analyzers are the most widely used equipments in clinical laboratories. A large quantity of reagents and other consumables are required for various types of tests. Basic metabolic panel tests are the largest test segment for the clinical chemistry analyzer market in 2014, whereas the lipid profile test segment is expected to grow at the highest CAGR between 2014 and 2019. Growth in the basic metabolic panel tests, aided by growing trends of preventive medicine and increasing incidence in lifestyle disease will drive the growth of the market. This report segments the global clinical chemistry analyzer market into analyzers, reagents and other products. The market is further sub segmented into Small (400-800 Test/H), Medium (800-1,200 Tests/H), Large (1,200-2,000 Tests/H), Very large (2,000 Tests/H). The clinical chemistry reagents market is sub segmented into calibrators, controls, standards and other reagents. The major players in the clinical chemistry analyzer market include Roche Diagnostics (Switzerland), Beckman Coulter (U.S.) Abbott Diagnostics (U.S.) Siemens AG (Germany), Ortho-Clinical Diagnostics (U.S.), Thermo Fisher Scientific (U.S.) Randox Laboratories Ltd. (U.K.), ElitechGroup (France), Mindray (China), Horiba (Japan). Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Clinical Chemistry Analyzers Market, By Product 8 Clinical Chemistry Analyzers Market, By Test 9 Clinical Chemistry Analyzers Market, By End Users 10 Geographic Analysis 11 Competitive Landscape 12 Company Profiles 13 Appendix Companies Mentioned: - Abbott Laboratories - Danaher Corporation - Elitech - F. Hoffmann-La Roche - Horiba - Johnson & Johnson - Mindray Medical International Limited - Randox Laboratories - Siemens - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/jzzrg4/clinical
JNJ: 108.77 (-0.30), ABT: 44.25 (-0.34), DHR: 82.08 (-0.32), MR: 30.90 (-0.32)
Total Return And Dividend Growth Investing
David Crosetti - at Seeking Alpha - Thu Nov 13, 2:50PM CST
KO: 42.91 (+0.12), JNJ: 108.77 (-0.30), ABT: 44.25 (-0.34), LMT: 186.53 (-1.44), KMB: 113.42 (-0.65), TGT: 67.53 (+0.03), WMT: 82.14 (-0.80), MCD: 96.59 (+1.11), PG: 88.58 (-0.02), CL: 68.01 (-0.28)
11 Earnings Reports Worth Paying Attention To
Brian Nelson - at Seeking Alpha - Thu Nov 13, 1:03PM CST
KO: 42.92 (+0.13), YHOO: 50.80 (+0.30), T: 36.12 (+0.51), ABT: 44.25 (-0.34), NSC: 115.87 (+0.42), UTX: 107.99 (-0.15), BRCM: 41.54 (-0.25), DDD: 33.02 (-0.37), KMB: 113.42 (-0.65), BA: 128.47 (-0.06), CLB: 138.70 (+1.69)
Research and Markets: Global Cardiac Biomarkers Market 2014-2018 with Abbott Laboratories, Alere, Ortho Clinical Diagnostics & Roche Diagnostics Dominating
Business Wire - Thu Nov 13, 8:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/9c49lp/global_cardiac) has announced the addition of the "Global Cardiac Biomarkers Market 2014-2018" report to their offering.
ABT: 44.25 (-0.34)
Research and Markets: Global BGM Device Market 2014-2018 with Abbott Laboratories, Arkray, Bayer Healthcare, F. Hoffmann-La Roche & LifeScan Dominating
Business Wire - Thu Nov 13, 8:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/bph2ng/global_bgm_device) has announced the addition of the "Global BGM Device Market 2014-2018" report to their offering.
ABT: 44.25 (-0.34)
Defibrillator Market to 2018 - Abbott Laboratories, Alere Inc., Ortho Clinical Diagnostics Inc. and Roche Diagnostics Analyzed
PRWeb - Thu Nov 13, 6:50AM CST
The Global Defibrillator Market 2014-2018 report says one of the major trends upcoming in the Defibrillator market is the growing use of multifunction defibrillators. The most important driver of the cardiovascular devices market is increased incidence of cardiac disorders. It is used to deliver a therapeutic dose of electrical energy in the form of electric shocks to the heart muscle for restoring normal heart rhythms.
ABT: 44.25 (-0.34), ALR: 39.86 (-0.15)
Global Cardiac Biomarkers Market 2014-2018 with Abbott Laboratories, Alere, Ortho Clinical Diagnostics & Roche Diagnostics Dominating
M2 - Thu Nov 13, 5:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/kbxkrr/global_cardiac) has announced the addition of the "Global Cardiac Biomarkers Market 2014-2018" report to their offering. The analysts forecast the Global Cardiac Biomarkers market to grow at a CAGR of 12.75% over the period 2013-2018 A cardiac biomarker is defined as a measurable substance that is an indicator used in the diagnosis and risk stratification related to cardiovascular disease (CVDs) such as acute coronary syndrome (ACS), coronary syndromes, myocardial infarction (MI), and heart failure. Some of the cardiac biomarkers include creatine kinase (CK) MB, troponins (cTnI and cTnT), BNP, NT-proBNP, GFAP, H-FABP, LDH isoenzymes, D-dimer, IMA, MPO, myoglobin, and sCD40L. Cardiac biomarker assays help medical professionals to understand and differentiate between myocardial infarction and angina, which assists in the diagnosis and treatment of CVDs. The abnormal concentration of these biomarkers will act as significant predictors of an adverse cardiovascular condition. Cardiac point of care (POC) testing offers reliable measurement of cardiac biomarkers and provides results within one hour of testing. In addition to saving time, some cardiac POC tests have been modified to improve the accuracy of the measurement of enzymes to reduce operational error. The identification of new cardiac biomarkers (H-FABP, GPBB, Urotensin II, and S-100 as potential cardiac biomarkers) and the advances being made in diagnostic technologies are some of the major trends uocoming in this market. According to the report, one of the major factors driving this market is the increase in the incidence of cardiac disorders. This increase in the incidence of CVDs, HF, and coronary syndromes is leading to increased adoption of cardiac POC tests because they provide rapid diagnostics for analyzing the specificity of the disease. Further, the report states that one key challenge in the market is the lack of specific measures to detect the presence of CVDs, which may have an adverse effect on patients because it may lead to incorrect diagnosis, and in serious cardiac conditions it may even cause death Key Vendors - Abbott Laboratories - Alere - Ortho Clinical Diagnostics - Roche Diagnostics For more information visit http://www.researchandmarkets.com/research/kb...al_cardiac
ABT: 44.25 (-0.34)
Global BGM Device Market 2014-2018 with Abbott Laboratories, Arkray, Bayer Healthcare, F. Hoffmann-La Roche & LifeScan Dominating
M2 - Thu Nov 13, 5:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/5x4zcw/global_bgm_device) has announced the addition of the "Global BGM Device Market 2014-2018" report to their offering. Diabetes is a disease that occurs when the body is unable to produce insulin, or when the glucose rises above the required levels. Insulin, a hormone produced by the pancreas, is used to process glucose, which acts as a fuel for the tissues. BGM is the process of testing the concentration of insulin or glucose in the blood. A blood glucose meter is a small electronic device used to measure and display the blood glucose level. To measure the level of blood glucose, a small drop of blood is taken by pricking a finger with an instrument called a lancet. The blood is then placed on a disposable blood glucose test strip and this is inserted into a blood glucose meter. One key trend emerging in the market is the change in the preference of patients to take advantage of home healthcare rather than going to hospitals. The move toward proactive monitoring rather than waiting for treatment is opening up new opportunities for the Global BGM Device market. According to the report, one of the main drivers in this market is the increasing incidence of diabetic patients. The increase in the prevalence of diabetes and the high market potential of diabetes products has encouraged various companies to explore the Global BGM Device market. Further, the report states that one of the main challenges in the market is the high cost of BGM devices. Despite the numerous benefits, the high cost of BGM devices hinders their acceptability among patients. Many patients do not have the required funds to invest in a device. To calculate the market size, the report considers the revenue generated from the sales of the three segments as mentioned below: - Blood Glucose Strips - Blood Glucose Meters - Lancets Key Vendors - Abbott Laboratories - Arkray - Bayer Healthcare - F. Hoffmann-La Roche - LifeScan For more information visit http://www.researchandmarkets.com/research/5x...bgm_device
ABT: 44.25 (-0.34)
Global Insulin Delivery Devices Market Outlook 2018
M2 - Thu Nov 13, 4:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/ttg7ws/global_insulin) has announced the addition of the "Global Insulin Delivery Devices Market Outlook 2018" report to their offering. In 2013, a total of 382 Million People had diabetes and by 2030 this number is expected to rise to 552 Million. This finding by the International Diabetes Federation (IDF) and similar results from studies done by organizations of repute such as WHO, CDC, NHS, etc., suggest that a huge patient population exists in the diabetes market. In 2013, health expenditure on diabetes accounted for around 10% of the total health expenditure globally. Of all the market segments that result from this multibillion dollar expenditure, insulin delivery devices represents one of the most rapidly expanding areas and is thus the key focus of this current study. In this latest research study Global Insulin Delivery Devices Market Outlook 2018, the analysts identified the market dynamics in various important regions to highlight the areas offering promising opportunities to companies for boosting their growth. Insulin delivery devices predominantly include Insulin Syringes, Insulin Pens (Disposable and Reusable), Insulin Pumps and Insulin Jet Injectors. Our study provides a comprehensive analysis of the delivery devices market, both at global and regional levels. This analysis includes the current market statistics, key drivers stimulating each segment's growth, and the future outlook of the segments. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Global Insulin Market Overview to 2018 4. Industry Trends and Drivers 5. Key Market Restraints 6. Global Insulin Delivery Devices Market Outlook to 2018 7. Insulin Delivery Devices: Current and Future Outlook to 2018 8. Emerging Devices 9. Key Players Companies Mentioned: - Abbott Laboratories - B. Braun Melsungen AG - Becton Dickinson - Eli Lilly - F. Hoffmann La Roche - Insulet Corporation - Johnson and Johnson - Medtronic - Novo Nordisk - Sanofi-Aventis - Ypsomed Holding AG For more information visit http://www.researchandmarkets.com/research/tt...al_insulin
JNJ: 108.77 (-0.30), ABT: 44.25 (-0.34), PODD: 45.39 (-0.42), NVO: 43.71 (-0.31), MDT: 69.06 (-0.32), LLY: 67.43 (-0.25)
Abbott Laboratories' (ABT) Presents at Credit Suisse Healthcare Conference -- Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 4:19PM CST
ABT: 44.25 (-0.34)
DexCom Scales 52-Week High on Product Pipeline Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 1:10PM CST
Impressive third-quarter 2014 results, recent FDA approvals for its new products along with a robust product pipeline contribute to the growth trajectory of DexCom, Inc. (DXCM), creating good momentum for 2015 as well.
ABT: 44.25 (-0.34), JNJ: 108.77 (-0.30), DXCM: 52.82 (-0.81), MDT: 69.06 (-0.32)
Global Syringes (Disposable and Reusable) Industry
PR Newswire - Tue Nov 11, 10:17AM CST
This report analyzes the worldwide markets for Syringes (Disposable and Reusable) in US$ Thousands by the following Product Segments: Anesthesia Syringes, Angiographic Syringes, Blood Gas Syringes, Catheter Syringes, Dental Syringes, Ear Syringes, Hypodermic Syringes (Prefilled Syringes, & Other Hypodermic Syringes), Insulin Syringes, Intraligamentary Syringes, and Irrigating Syringes. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 109 companies including many key and niche players such as -
ABT: 44.25 (-0.34)
U.S. Market for Peripheral Vascular Devices and Accessories Executive Summary: By 2020, the U.S. market for peripheral vascular devices will be worth over $6 billion
M2 - Tue Nov 11, 6:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/3rwwd3/u_s_market_for) has announced the addition of the "U.S. Market for Peripheral Vascular Devices and Accessories (Executive Summary)" report to their offering. The peripheral vascular device market includes stents, percutaneous transluminal angioplasty (PTA) balloon catheters, atherectomy devices, chronic total occlusion devices, stent grafts, surgical grafts, arteriovenous (AV) access thrombectomy devices, inferior vena cava filters, catheters, guidewires, introducer sheaths, vascular closure devices and transcatheter embolization devices. These devices can be used for treating either coronary arterial or peripheral arterial disease (PAD), but only those devices used for peripheral procedures are included in this report. Older individuals and those who are obese have a higher risk of developing PAD. As result of a general increase in peripheral procedures and the development of new lower-limb treatments, the market for products such as stents and stent grafts will grow rapidly in the U.S. over the forecast period. Peripheral artery disease (PAD) remains a significantly under treated condition in the U.S and PAD is the leading cause of leg amputation. These factors will continue to drive growth in the peripheral vascular device market. In particular, the peripheral stent market is projected to grow over the forecast period. However, intense competition has led to price erosion and market penetration has moderated this once high growth segment. The launch of new technologies, including drug-eluting stents, will generate marginal revenues and only one company has sought FDA approval. In contrast, significant investments and acquisitions have taken place in the efforts of bringing the first drug-eluting balloon to the market, with Medtronic and C. R. Bard in a tight race to gain approval. Scope - Competitor Analysis - Identified Strategic Opportunities - Market Overview by Segment - Trend Analysis by Segment - Market Drivers & Limiters - Mergers & Acquisitions - Customer Feedback and Market Monitoring Main Segments Included: - Peripheral Vascular Stent Market - PTA Balloon Catheter Market - Atherectomy Device Market - Chronic Total Occlusion (CTO) Device Market - Embolic Protection Device Market - Stent Graft Market - Surgical Graft Market - AV Access Thrombectomy Device Market - Inferior Vena Cava Filter Market - Diagnostic and Interventional Catheter Market - Diagnostic and Interventional Guidewire Market - Introducer Sheath Market - Vascular Closure Device Market - Transcatheter Embolization Device Market Companies Mentioned - ALN International Inc. - Abbott Laboratories - AccessClosure - AngioDynamics - AngioScore - Angiotech - Argon Medical - Arstasis - Artegraft - Asahi Intecc USA - Atrax - Atrium Medical - B. Braun - Boston Scientific - C. R. Bard - Cardiovascular Systems Inc - Cardiva CeloNova Biosciences - Cook Medical - Cordis - Covidien - Endologix - IDEV Technologies - LeMaitre Vascular - MEDRAD - Maquet - Marine Polymer Technologies - Medtronic - Morris Innovative - Penumbra - Pfizer For more information visit http://www.researchandmarkets.com/research/3r...market_for About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
BSX: 13.40 (-0.01), ABT: 44.25 (-0.34), MDT: 69.06 (-0.32), CSII: 28.99 (-0.18), LMAT: 7.13 (-0.01)
Look for Shares of Abbott Laboratories to Potentially Pullback after Yesterday's 1.66% Rise
Comtex SmarTrend(R) - Mon Nov 10, 4:03PM CST
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $43.17 to a high of $44.10. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $43.99 on volume of 5.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ABT: 44.25 (-0.34)
DexCom G4 Platinum Software Gains FDA Nod, Shares Surge - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 1:54PM CST
Following the announcement, shares of DexCom, Inc. (DXCM) shot up nearly 14.12% to close at $50.93 in the last trading session.
ABT: 44.25 (-0.34), JNJ: 108.75 (-0.32), DXCM: 52.82 (-0.81), MDT: 69.06 (-0.32)
Abbott Looks Overvalued On A Fundamental Basis
Stock Traders Daily - at Seeking Alpha - Fri Nov 07, 9:51AM CST
ABT: 44.25 (-0.34)
5 Things AbbVie Inc.'s Management Wants You to Know
Keith Speights, The Motley Fool - Motley Fool - Thu Nov 06, 11:38AM CST
Another quarter for AbbVie , another blow-out. The company announced strong third-quarter results last Friday. AbbVie's storyline behind those earnings, though, is probably more important than the numbers themselves. Here are five things the...
ABT: 44.25 (-0.34), GILD: 102.06 (-2.14), ABBV: 63.26 (-0.37)
Global Polymerase Chain Reaction (PCR) Market 2014-2018: Key Vendors are Abbott Laboratories, Agilent Technologies, Bio-Rad Laboratories, GE Healthcare and Thermo Fisher Scientific
M2 - Thu Nov 06, 5:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/slnt9m/global_polymerase) has announced the addition of the "Global Polymerase Chain Reaction (PCR) Market 2014-2018" report to their offering. Polymerase Chain Reaction (PCR) is a technique of molecular genetics, which allows amplification and analysis of nucleic acid. It is very precise, specific and accurate technique used to amplify a specific DNA target from a mixture of DNA molecules. It is used in a wide array of applications in research and diagnosis, including genetic engineering, cloning, sequencing, diagnosis, genotyping, and many other areas. Advances in PCR technology and tools provide high reproducibility within a short period of time. Depending on the requirement, PCR involves different types of reagents, consumables and instruments to process the sample. Advanced software helps to analyze the data generated from the sample processing. The analysts forecast the Global Polymerase Chain Reaction market to grow at a CAGR of 9.19 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Polymerase Chain Reaction market for the period 2014-2018. To calculate the market size, the report considers revenue generated from sales of products used in PCR. The products considered within the scope of the report are PCR reagents and consumables, instruments, and software and services, which are required to perform PCR. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Product 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis 18. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Affimetrix - Agilent Technologies - BD - Bio-Rad Laboratories - Cepheid - Danaher - Eppendorf - F. Hoffmann-La Roche - Fluidigm - GE Healthcare - Harvard Bioscience - Illumin - PerkinElmer - Promega - Qiagen - RainDanceTechnologies - Sigma-Aldrich - Takara Bio - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/sl...polymerase
ABT: 44.25 (-0.34), A: 41.50 (+0.05), CPHD: 52.75 (-1.26), DHR: 82.10 (-0.30), PKI: 43.51 (-0.03)
Global Drug Abuse Testing Market Outlook 2018 - Increase in Number of Collaborations and M&A
M2 - Thu Nov 06, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/dtmmdp/global_drug_abuse) has announced the addition of the "Global Drug Abuse Testing Market 2014-2018" report to their offering. The Global Drug Abuse Testing market to grow at a CAGR of 4.71% over the period 2013-2018 To calculate the market size, the report considers the revenue generated from sales of drug abuse testing solutions, which includes drug abuse testing kits and systems. The technologies primarily considered in the report are immunoassay and chromatography. One of the major trends upcoming in the market is the increase in the number of collaborations and M&A in the market. This strategy helps vendors to expand their portfolio as well as improve the quality and performance of their products. According to the report, the rising consumption of illicit drugs is a major driver in the Global Drug Abuse Testing market as the use of illicit drugs in developed as well as in developing countries is increasing worldwide. Further, the report states that one of the key challenges that the market faces is the inability of drug abuse testing products to detect low-dose designer drugs. The detection of designer drugs such as ecstasy, Rohypnol, and LSD is very difficult. Key Vendors - Bio-Rad Laboratories - Danaher - F. Hoffmann-La Roche - Siemens - Thermo Fisher Scientific Other Prominent Vendors - Abbott Laboratories - Agilent Technologies - Alere - Biomedical Diagnostics - Branan Medical - OraSure Technologies - PerkinElmer - Psychemedics - Quest Diagnostic - Randox Laboratories - Sigma-Aldrich - Sonic Healthcare - Waters Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Overview - Market Landscape - Market Segmentation by Technique - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/dt...drug_abuse
PMD: 15.25 (+0.11), ABT: 44.25 (-0.34), A: 41.50 (+0.05), DHR: 82.10 (-0.30), PKI: 43.51 (-0.03), OSUR: 8.95 (-0.01)
Abbott to Present at Credit Suisse 2014 Healthcare Conference
PR Newswire - Tue Nov 04, 8:00AM CST
Abbott (NYSE: ABT) will participate in the Credit Suisse 2014 Healthcare Conference on Tuesday, Nov. 11, 2014. Thomas C. Freyman, executive vice president, finance and chief financial officer, will make a formal presentation on the company beginning at 12 p.m. Central time.
ABT: 44.25 (-0.34)
ABT Recent Posts: http://investorshangout.com/Abbott-Laboratories-ABT-49973/
ABT Abbott Laboratories Recent Headline News
Global Clinical Chemistry Analyzer (Basic Metabolic, Electrolyte, Liver, Lipid, Renal, Thyroid Function, Specialty Chemicals) Market - Forecast to 2019
M2 - Fri Nov 14, 5:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/jzzrg4/clinical) has announced the addition of the "Clinical Chemistry Analyzer Market by Product, Test Type, End User - Global Forecast to 2019" report to their offering. Clinical chemistry analyzers are the most widely used equipments in clinical laboratories. A large quantity of reagents and other consumables are required for various types of tests. Basic metabolic panel tests are the largest test segment for the clinical chemistry analyzer market in 2014, whereas the lipid profile test segment is expected to grow at the highest CAGR between 2014 and 2019. Growth in the basic metabolic panel tests, aided by growing trends of preventive medicine and increasing incidence in lifestyle disease will drive the growth of the market. This report segments the global clinical chemistry analyzer market into analyzers, reagents and other products. The market is further sub segmented into Small (400-800 Test/H), Medium (800-1,200 Tests/H), Large (1,200-2,000 Tests/H), Very large (2,000 Tests/H). The clinical chemistry reagents market is sub segmented into calibrators, controls, standards and other reagents. The major players in the clinical chemistry analyzer market include Roche Diagnostics (Switzerland), Beckman Coulter (U.S.) Abbott Diagnostics (U.S.) Siemens AG (Germany), Ortho-Clinical Diagnostics (U.S.), Thermo Fisher Scientific (U.S.) Randox Laboratories Ltd. (U.K.), ElitechGroup (France), Mindray (China), Horiba (Japan). Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Clinical Chemistry Analyzers Market, By Product 8 Clinical Chemistry Analyzers Market, By Test 9 Clinical Chemistry Analyzers Market, By End Users 10 Geographic Analysis 11 Competitive Landscape 12 Company Profiles 13 Appendix Companies Mentioned: - Abbott Laboratories - Danaher Corporation - Elitech - F. Hoffmann-La Roche - Horiba - Johnson & Johnson - Mindray Medical International Limited - Randox Laboratories - Siemens - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/jzzrg4/clinical
JNJ: 108.77 (-0.30), ABT: 44.25 (-0.34), DHR: 82.08 (-0.32), MR: 30.90 (-0.32)
Total Return And Dividend Growth Investing
David Crosetti - at Seeking Alpha - Thu Nov 13, 2:50PM CST
KO: 42.91 (+0.12), JNJ: 108.77 (-0.30), ABT: 44.25 (-0.34), LMT: 186.53 (-1.44), KMB: 113.42 (-0.65), TGT: 67.53 (+0.03), WMT: 82.14 (-0.80), MCD: 96.59 (+1.11), PG: 88.58 (-0.02), CL: 68.01 (-0.28)
11 Earnings Reports Worth Paying Attention To
Brian Nelson - at Seeking Alpha - Thu Nov 13, 1:03PM CST
KO: 42.92 (+0.13), YHOO: 50.80 (+0.30), T: 36.12 (+0.51), ABT: 44.25 (-0.34), NSC: 115.87 (+0.42), UTX: 107.99 (-0.15), BRCM: 41.54 (-0.25), DDD: 33.02 (-0.37), KMB: 113.42 (-0.65), BA: 128.47 (-0.06), CLB: 138.70 (+1.69)
Research and Markets: Global Cardiac Biomarkers Market 2014-2018 with Abbott Laboratories, Alere, Ortho Clinical Diagnostics & Roche Diagnostics Dominating
Business Wire - Thu Nov 13, 8:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/9c49lp/global_cardiac) has announced the addition of the "Global Cardiac Biomarkers Market 2014-2018" report to their offering.
ABT: 44.25 (-0.34)
Research and Markets: Global BGM Device Market 2014-2018 with Abbott Laboratories, Arkray, Bayer Healthcare, F. Hoffmann-La Roche & LifeScan Dominating
Business Wire - Thu Nov 13, 8:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/bph2ng/global_bgm_device) has announced the addition of the "Global BGM Device Market 2014-2018" report to their offering.
ABT: 44.25 (-0.34)
Defibrillator Market to 2018 - Abbott Laboratories, Alere Inc., Ortho Clinical Diagnostics Inc. and Roche Diagnostics Analyzed
PRWeb - Thu Nov 13, 6:50AM CST
The Global Defibrillator Market 2014-2018 report says one of the major trends upcoming in the Defibrillator market is the growing use of multifunction defibrillators. The most important driver of the cardiovascular devices market is increased incidence of cardiac disorders. It is used to deliver a therapeutic dose of electrical energy in the form of electric shocks to the heart muscle for restoring normal heart rhythms.
ABT: 44.25 (-0.34), ALR: 39.86 (-0.15)
Global Cardiac Biomarkers Market 2014-2018 with Abbott Laboratories, Alere, Ortho Clinical Diagnostics & Roche Diagnostics Dominating
M2 - Thu Nov 13, 5:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/kbxkrr/global_cardiac) has announced the addition of the "Global Cardiac Biomarkers Market 2014-2018" report to their offering. The analysts forecast the Global Cardiac Biomarkers market to grow at a CAGR of 12.75% over the period 2013-2018 A cardiac biomarker is defined as a measurable substance that is an indicator used in the diagnosis and risk stratification related to cardiovascular disease (CVDs) such as acute coronary syndrome (ACS), coronary syndromes, myocardial infarction (MI), and heart failure. Some of the cardiac biomarkers include creatine kinase (CK) MB, troponins (cTnI and cTnT), BNP, NT-proBNP, GFAP, H-FABP, LDH isoenzymes, D-dimer, IMA, MPO, myoglobin, and sCD40L. Cardiac biomarker assays help medical professionals to understand and differentiate between myocardial infarction and angina, which assists in the diagnosis and treatment of CVDs. The abnormal concentration of these biomarkers will act as significant predictors of an adverse cardiovascular condition. Cardiac point of care (POC) testing offers reliable measurement of cardiac biomarkers and provides results within one hour of testing. In addition to saving time, some cardiac POC tests have been modified to improve the accuracy of the measurement of enzymes to reduce operational error. The identification of new cardiac biomarkers (H-FABP, GPBB, Urotensin II, and S-100 as potential cardiac biomarkers) and the advances being made in diagnostic technologies are some of the major trends uocoming in this market. According to the report, one of the major factors driving this market is the increase in the incidence of cardiac disorders. This increase in the incidence of CVDs, HF, and coronary syndromes is leading to increased adoption of cardiac POC tests because they provide rapid diagnostics for analyzing the specificity of the disease. Further, the report states that one key challenge in the market is the lack of specific measures to detect the presence of CVDs, which may have an adverse effect on patients because it may lead to incorrect diagnosis, and in serious cardiac conditions it may even cause death Key Vendors - Abbott Laboratories - Alere - Ortho Clinical Diagnostics - Roche Diagnostics For more information visit http://www.researchandmarkets.com/research/kb...al_cardiac
ABT: 44.25 (-0.34)
Global BGM Device Market 2014-2018 with Abbott Laboratories, Arkray, Bayer Healthcare, F. Hoffmann-La Roche & LifeScan Dominating
M2 - Thu Nov 13, 5:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/5x4zcw/global_bgm_device) has announced the addition of the "Global BGM Device Market 2014-2018" report to their offering. Diabetes is a disease that occurs when the body is unable to produce insulin, or when the glucose rises above the required levels. Insulin, a hormone produced by the pancreas, is used to process glucose, which acts as a fuel for the tissues. BGM is the process of testing the concentration of insulin or glucose in the blood. A blood glucose meter is a small electronic device used to measure and display the blood glucose level. To measure the level of blood glucose, a small drop of blood is taken by pricking a finger with an instrument called a lancet. The blood is then placed on a disposable blood glucose test strip and this is inserted into a blood glucose meter. One key trend emerging in the market is the change in the preference of patients to take advantage of home healthcare rather than going to hospitals. The move toward proactive monitoring rather than waiting for treatment is opening up new opportunities for the Global BGM Device market. According to the report, one of the main drivers in this market is the increasing incidence of diabetic patients. The increase in the prevalence of diabetes and the high market potential of diabetes products has encouraged various companies to explore the Global BGM Device market. Further, the report states that one of the main challenges in the market is the high cost of BGM devices. Despite the numerous benefits, the high cost of BGM devices hinders their acceptability among patients. Many patients do not have the required funds to invest in a device. To calculate the market size, the report considers the revenue generated from the sales of the three segments as mentioned below: - Blood Glucose Strips - Blood Glucose Meters - Lancets Key Vendors - Abbott Laboratories - Arkray - Bayer Healthcare - F. Hoffmann-La Roche - LifeScan For more information visit http://www.researchandmarkets.com/research/5x...bgm_device
ABT: 44.25 (-0.34)
Global Insulin Delivery Devices Market Outlook 2018
M2 - Thu Nov 13, 4:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/ttg7ws/global_insulin) has announced the addition of the "Global Insulin Delivery Devices Market Outlook 2018" report to their offering. In 2013, a total of 382 Million People had diabetes and by 2030 this number is expected to rise to 552 Million. This finding by the International Diabetes Federation (IDF) and similar results from studies done by organizations of repute such as WHO, CDC, NHS, etc., suggest that a huge patient population exists in the diabetes market. In 2013, health expenditure on diabetes accounted for around 10% of the total health expenditure globally. Of all the market segments that result from this multibillion dollar expenditure, insulin delivery devices represents one of the most rapidly expanding areas and is thus the key focus of this current study. In this latest research study Global Insulin Delivery Devices Market Outlook 2018, the analysts identified the market dynamics in various important regions to highlight the areas offering promising opportunities to companies for boosting their growth. Insulin delivery devices predominantly include Insulin Syringes, Insulin Pens (Disposable and Reusable), Insulin Pumps and Insulin Jet Injectors. Our study provides a comprehensive analysis of the delivery devices market, both at global and regional levels. This analysis includes the current market statistics, key drivers stimulating each segment's growth, and the future outlook of the segments. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Global Insulin Market Overview to 2018 4. Industry Trends and Drivers 5. Key Market Restraints 6. Global Insulin Delivery Devices Market Outlook to 2018 7. Insulin Delivery Devices: Current and Future Outlook to 2018 8. Emerging Devices 9. Key Players Companies Mentioned: - Abbott Laboratories - B. Braun Melsungen AG - Becton Dickinson - Eli Lilly - F. Hoffmann La Roche - Insulet Corporation - Johnson and Johnson - Medtronic - Novo Nordisk - Sanofi-Aventis - Ypsomed Holding AG For more information visit http://www.researchandmarkets.com/research/tt...al_insulin
JNJ: 108.77 (-0.30), ABT: 44.25 (-0.34), PODD: 45.39 (-0.42), NVO: 43.71 (-0.31), MDT: 69.06 (-0.32), LLY: 67.43 (-0.25)
Abbott Laboratories' (ABT) Presents at Credit Suisse Healthcare Conference -- Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 4:19PM CST
ABT: 44.25 (-0.34)
DexCom Scales 52-Week High on Product Pipeline Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 1:10PM CST
Impressive third-quarter 2014 results, recent FDA approvals for its new products along with a robust product pipeline contribute to the growth trajectory of DexCom, Inc. (DXCM), creating good momentum for 2015 as well.
ABT: 44.25 (-0.34), JNJ: 108.77 (-0.30), DXCM: 52.82 (-0.81), MDT: 69.06 (-0.32)
Global Syringes (Disposable and Reusable) Industry
PR Newswire - Tue Nov 11, 10:17AM CST
This report analyzes the worldwide markets for Syringes (Disposable and Reusable) in US$ Thousands by the following Product Segments: Anesthesia Syringes, Angiographic Syringes, Blood Gas Syringes, Catheter Syringes, Dental Syringes, Ear Syringes, Hypodermic Syringes (Prefilled Syringes, & Other Hypodermic Syringes), Insulin Syringes, Intraligamentary Syringes, and Irrigating Syringes. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 109 companies including many key and niche players such as -
ABT: 44.25 (-0.34)
U.S. Market for Peripheral Vascular Devices and Accessories Executive Summary: By 2020, the U.S. market for peripheral vascular devices will be worth over $6 billion
M2 - Tue Nov 11, 6:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/3rwwd3/u_s_market_for) has announced the addition of the "U.S. Market for Peripheral Vascular Devices and Accessories (Executive Summary)" report to their offering. The peripheral vascular device market includes stents, percutaneous transluminal angioplasty (PTA) balloon catheters, atherectomy devices, chronic total occlusion devices, stent grafts, surgical grafts, arteriovenous (AV) access thrombectomy devices, inferior vena cava filters, catheters, guidewires, introducer sheaths, vascular closure devices and transcatheter embolization devices. These devices can be used for treating either coronary arterial or peripheral arterial disease (PAD), but only those devices used for peripheral procedures are included in this report. Older individuals and those who are obese have a higher risk of developing PAD. As result of a general increase in peripheral procedures and the development of new lower-limb treatments, the market for products such as stents and stent grafts will grow rapidly in the U.S. over the forecast period. Peripheral artery disease (PAD) remains a significantly under treated condition in the U.S and PAD is the leading cause of leg amputation. These factors will continue to drive growth in the peripheral vascular device market. In particular, the peripheral stent market is projected to grow over the forecast period. However, intense competition has led to price erosion and market penetration has moderated this once high growth segment. The launch of new technologies, including drug-eluting stents, will generate marginal revenues and only one company has sought FDA approval. In contrast, significant investments and acquisitions have taken place in the efforts of bringing the first drug-eluting balloon to the market, with Medtronic and C. R. Bard in a tight race to gain approval. Scope - Competitor Analysis - Identified Strategic Opportunities - Market Overview by Segment - Trend Analysis by Segment - Market Drivers & Limiters - Mergers & Acquisitions - Customer Feedback and Market Monitoring Main Segments Included: - Peripheral Vascular Stent Market - PTA Balloon Catheter Market - Atherectomy Device Market - Chronic Total Occlusion (CTO) Device Market - Embolic Protection Device Market - Stent Graft Market - Surgical Graft Market - AV Access Thrombectomy Device Market - Inferior Vena Cava Filter Market - Diagnostic and Interventional Catheter Market - Diagnostic and Interventional Guidewire Market - Introducer Sheath Market - Vascular Closure Device Market - Transcatheter Embolization Device Market Companies Mentioned - ALN International Inc. - Abbott Laboratories - AccessClosure - AngioDynamics - AngioScore - Angiotech - Argon Medical - Arstasis - Artegraft - Asahi Intecc USA - Atrax - Atrium Medical - B. Braun - Boston Scientific - C. R. Bard - Cardiovascular Systems Inc - Cardiva CeloNova Biosciences - Cook Medical - Cordis - Covidien - Endologix - IDEV Technologies - LeMaitre Vascular - MEDRAD - Maquet - Marine Polymer Technologies - Medtronic - Morris Innovative - Penumbra - Pfizer For more information visit http://www.researchandmarkets.com/research/3r...market_for About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
BSX: 13.40 (-0.01), ABT: 44.25 (-0.34), MDT: 69.06 (-0.32), CSII: 28.99 (-0.18), LMAT: 7.13 (-0.01)
Look for Shares of Abbott Laboratories to Potentially Pullback after Yesterday's 1.66% Rise
Comtex SmarTrend(R) - Mon Nov 10, 4:03PM CST
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $43.17 to a high of $44.10. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $43.99 on volume of 5.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ABT: 44.25 (-0.34)
DexCom G4 Platinum Software Gains FDA Nod, Shares Surge - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 1:54PM CST
Following the announcement, shares of DexCom, Inc. (DXCM) shot up nearly 14.12% to close at $50.93 in the last trading session.
ABT: 44.25 (-0.34), JNJ: 108.75 (-0.32), DXCM: 52.82 (-0.81), MDT: 69.06 (-0.32)
Abbott Looks Overvalued On A Fundamental Basis
Stock Traders Daily - at Seeking Alpha - Fri Nov 07, 9:51AM CST
ABT: 44.25 (-0.34)
5 Things AbbVie Inc.'s Management Wants You to Know
Keith Speights, The Motley Fool - Motley Fool - Thu Nov 06, 11:38AM CST
Another quarter for AbbVie , another blow-out. The company announced strong third-quarter results last Friday. AbbVie's storyline behind those earnings, though, is probably more important than the numbers themselves. Here are five things the...
ABT: 44.25 (-0.34), GILD: 102.06 (-2.14), ABBV: 63.26 (-0.37)
Global Polymerase Chain Reaction (PCR) Market 2014-2018: Key Vendors are Abbott Laboratories, Agilent Technologies, Bio-Rad Laboratories, GE Healthcare and Thermo Fisher Scientific
M2 - Thu Nov 06, 5:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/slnt9m/global_polymerase) has announced the addition of the "Global Polymerase Chain Reaction (PCR) Market 2014-2018" report to their offering. Polymerase Chain Reaction (PCR) is a technique of molecular genetics, which allows amplification and analysis of nucleic acid. It is very precise, specific and accurate technique used to amplify a specific DNA target from a mixture of DNA molecules. It is used in a wide array of applications in research and diagnosis, including genetic engineering, cloning, sequencing, diagnosis, genotyping, and many other areas. Advances in PCR technology and tools provide high reproducibility within a short period of time. Depending on the requirement, PCR involves different types of reagents, consumables and instruments to process the sample. Advanced software helps to analyze the data generated from the sample processing. The analysts forecast the Global Polymerase Chain Reaction market to grow at a CAGR of 9.19 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Polymerase Chain Reaction market for the period 2014-2018. To calculate the market size, the report considers revenue generated from sales of products used in PCR. The products considered within the scope of the report are PCR reagents and consumables, instruments, and software and services, which are required to perform PCR. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Product 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis 18. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Affimetrix - Agilent Technologies - BD - Bio-Rad Laboratories - Cepheid - Danaher - Eppendorf - F. Hoffmann-La Roche - Fluidigm - GE Healthcare - Harvard Bioscience - Illumin - PerkinElmer - Promega - Qiagen - RainDanceTechnologies - Sigma-Aldrich - Takara Bio - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/sl...polymerase
ABT: 44.25 (-0.34), A: 41.50 (+0.05), CPHD: 52.75 (-1.26), DHR: 82.10 (-0.30), PKI: 43.51 (-0.03)
Global Drug Abuse Testing Market Outlook 2018 - Increase in Number of Collaborations and M&A
M2 - Thu Nov 06, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/dtmmdp/global_drug_abuse) has announced the addition of the "Global Drug Abuse Testing Market 2014-2018" report to their offering. The Global Drug Abuse Testing market to grow at a CAGR of 4.71% over the period 2013-2018 To calculate the market size, the report considers the revenue generated from sales of drug abuse testing solutions, which includes drug abuse testing kits and systems. The technologies primarily considered in the report are immunoassay and chromatography. One of the major trends upcoming in the market is the increase in the number of collaborations and M&A in the market. This strategy helps vendors to expand their portfolio as well as improve the quality and performance of their products. According to the report, the rising consumption of illicit drugs is a major driver in the Global Drug Abuse Testing market as the use of illicit drugs in developed as well as in developing countries is increasing worldwide. Further, the report states that one of the key challenges that the market faces is the inability of drug abuse testing products to detect low-dose designer drugs. The detection of designer drugs such as ecstasy, Rohypnol, and LSD is very difficult. Key Vendors - Bio-Rad Laboratories - Danaher - F. Hoffmann-La Roche - Siemens - Thermo Fisher Scientific Other Prominent Vendors - Abbott Laboratories - Agilent Technologies - Alere - Biomedical Diagnostics - Branan Medical - OraSure Technologies - PerkinElmer - Psychemedics - Quest Diagnostic - Randox Laboratories - Sigma-Aldrich - Sonic Healthcare - Waters Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Overview - Market Landscape - Market Segmentation by Technique - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/dt...drug_abuse
PMD: 15.25 (+0.11), ABT: 44.25 (-0.34), A: 41.50 (+0.05), DHR: 82.10 (-0.30), PKI: 43.51 (-0.03), OSUR: 8.95 (-0.01)
Abbott to Present at Credit Suisse 2014 Healthcare Conference
PR Newswire - Tue Nov 04, 8:00AM CST
Abbott (NYSE: ABT) will participate in the Credit Suisse 2014 Healthcare Conference on Tuesday, Nov. 11, 2014. Thomas C. Freyman, executive vice president, finance and chief financial officer, will make a formal presentation on the company beginning at 12 p.m. Central time.
ABT: 44.25 (-0.34)
(0)
(0)Abbott Laboratories (ABT) Stock Research Links
Scroll down for more posts ▼